The 5th PVRI Annual Drug Discovery & Development Symposium for Pulmonary Hypertension was held on 9-10 July in Bethesda, Maryland, USA, and brought together a large group of expert clinicians and academicians, industry representatives, and members of the US Food and Drug Administration, among many other interested parties. The conference emphasised three contemporary issues in the context of pulmonary vascular disease treatment: repurposing of existing drug therapies; identifying novel pharmacotherapeutic targets; and forward-thinking approaches to phenotyping patients for clinical trial enrolment.
The meeting was a huge success, with invigorating presentations and lively interaction between presenters, moderators, and attendees alike. There were many highlights, including presentations showcasing early clinical data on the promising therapeutic role of dichloroacetate and recombinant ACE2 for PAH, as well as the adenosine partial A1 receptor agonist neladenson for heart failure with preserved ejection fraction patients. In addition, exciting presentations from world experts on systems pharmacology and mechanical circulatory support cast important light on the potential of each strategy to improve clinical outcomes. Another popular theme emphasised methods for earlier identification of PAH patients. In this segment, discussions on recent advances using non-invasive imaging to detect pulmonary vascular remodelling, as well as fresh perspective on the haemodynamic criteria that define risk early in pulmonary hypertension suggested that important opportunity exists in the near future to optimise diagnosis and treatment of our patients.
We look forward to carrying forward the productivity and momentum from this conference series to the next PVRI Drug Discovery & Development Symposium, which will be held in Paris in July 2019. Mark your calendars and see you there!